Combined Checklist for Commencing Revlimid®▼ (lenalidomide) Treatment

This checklist is to assist you with counselling a patient before they commence Revlimid treatment in order to assure it is used safely and correctly. Please choose the applicable column for the risk category of the patient and refer to the counselling messages provided.

Counselling	Women of Childbearing Potential	Women of Non-Childbearing Potential*	Male
Inform of expected teratogenic risk to the unborn child	●	●	●
Inform of the need for effective contraception** for at least 4 weeks before starting treatment, throughout the entire duration of treatment, including during treatment interruptions, and for at least 4 weeks after the end of treatment, or absolute and continued abstinence	●		
Inform of the requirement to discuss with the prescriber prescribing Revlimid and the contraception method if the patient needs to change or stop their method of contraception	●		
Inform that even if patient has amenorrhoea they must comply with advice on contraception	●		
Confirm patient is capable of complying with contraceptive measures	●		●
Inform of the expected consequences of pregnancy and the need to consult rapidly if there is a risk of pregnancy	●		●
Inform of the need to stop treatment immediately if female patient is suspected to be pregnant	●		
Confirm patient agrees to undergo pregnancy testing at least in 4 weekly intervals unless confirmed tubal sterilisation	●		
Inform of hazards and necessary precautions associated with use of Revlimid	●	●	●
Inform patient not to share medication	●	●	●
Inform to return unused capsules to pharmacist	●	●	●
Inform not to donate blood whilst taking Revlimid, during treatment interruptions and for at least 7 days following discontinuation	●	●	●
Inform of the need to use condoms, including those who have had a vasectomy as seminal fluid may still contain Revlimid in the absence of spermatozoa, throughout treatment duration, during dose interruption, and for at least 7 days after cessation of treatment if partner is pregnant or of childbearing potential not using effective contraception			●
Inform of the need not to donate semen or sperm during treatment, during dose interruptions, and for at least 7 days following discontinuation			●
Inform about the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with Revlimid	●	●	●
Inform about which are effective contraceptive methods that she or the female partner of a male patient can use	●		●
Inform that if his female partner becomes pregnant whilst he is taking Revlimid or shortly after he has stopped taking Revlimid, he should inform his prescriber immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice			●

* Refer to Healthcare Professional Information brochure and Summary of Product Characteristics (SmPC) for criteria to determine if patient is a woman of non-childbearing potential.

** Refer to Healthcare Professional Information brochure and SmPC for information on contraception.

Date of preparation of text: April 2022
Approved by MHRA: November 2022
Version 10

Combined Checklist for Commencing Revlimid®▼ (lenalidomide) Treatment

This checklist is to assist you with counselling a patient before they commence Revlimid treatment in order to assure it is used safely and correctly. Please choose the applicable column for the risk category of the patient and refer to the counselling messages provided.

Contraceptive referral	Women of Childbearing Potential	Women of Non-Childbearing Potential*	Male
Contraceptive referral required	●		
Contraceptive referral made	●		
Contraceptive consultation completed	●		

Contraception Patient is currently established on one of the following for at least 4 weeks	Women of Childbearing Potential	Women of Non-Childbearing Potential*	Male
Implant	●		
Levonorgestrel-releasing intrauterine system (IUS)	●		
Medroxyprogesterone acetate depot	●		
Tubal sterilisation	●		
Sexual intercourse with a vasectomised male partner only: vasectomy must be confirmed by negative semen analyses	●		
Ovulation inhibitory progesterone-only pill (desogestrel)	●		
Patient commits to absolute and continuous abstinence confirmed on a monthly basis	●		
Negative pregnancy test before starting treatment	●		

Not of childbearing potential One of the following criteria have been met to determine patient is women NCBP	Women of Childbearing Potential	Women of Non-Childbearing Potential*	Male
Age ≥50 years and naturally amenorrhoeaic*** for ≥1 year not induced by chemotherapy		●	
Premature ovarian failure confirmed by specialist gynaecologist		●	
Bilateral salpingo-oophorectomy, or hysterectomy		●	
XV genotype, Turner syndrome, uterine agenesis		●	

TREATMENT FOR A WOMAN OF CHILDBEARING POTENTIAL CANNOT START UNTIL THE PATIENT IS ESTABLISHED ON AT LEAST ONE EFFECTIVE METHOD OF CONTRACEPTION FOR AT LEAST 4 WEEKS PRIOR TO INITIATION OF THERAPY OR COMMITS TO ABSOLUTE AND CONTINUOUS ABSTINENCE CONFIRMED ON A MONTHLY BASIS AND PREGNANCY TEST IS NEGATIVE.

* Refer to Healthcare Professional Information brochure and SmPC for criteria to determine if patient is a woman of non-childbearing potential.
*** Amenorrhoea following cancer therapy or during breastfeeding does not rule out childbearing potential

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse drug reactions (ADRs) via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

Date of preparation of text: April 2022
Approved by MHRA: November 2022
Version 10

Pharmacy Registration and Dispensing of Revlimid®▼ (lenalidomide)



▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse drug reactions (ADRs) via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

Date of preparation of text: April 2022
Approved by MHRA: November 2022

2003-GB-2200044
Version 10